Published in final edited form as:

J Am Chem Soc. 2007 February 28; 129(8): 2206–2207. doi:10.1021/ja067305j.

Synthesis of a Ring Expanded Bryostatin Analogue

Barry M. Trost, Hanbiao Yang, Oliver R. Thiel, Alison J. Frontier, and Cheyenne S. Brindle

Department of Chemistry, Stanford University, Stanford, CA 94305

Abstract

A ring expanded bryostatin analogue was synthesized by utilizing a Ru-catalyzed tandem tetrahydropyran formation, a Pd-catalyzed tandem dihydropyran formation, and a ring-closing metathesis (RCM) as key steps. The analogue possesses potent anti-tumor activity against the NCI-ADR cancer cell line with an IC₅₀ of 123 nM.

The bryostatins are a family of marine natural products that display a wide range of biological activities, most notably their anticancer activity *in vivo*.¹ This effect is attributed to their ability to modulate the functions of protein kinase C isozymes within cells. One of the members of this family, bryostatin 1, is currently in several phase I and phase II clinical trials for the treatment of several cancers.² The syntheses of bryostatins and their analogues have been an active research area since the structure elucidation of bryostatin 1 in 1982.³ To date, three total and one formal syntheses have been reported^{4–7} and potent bryostatin analogues⁸ have been identified. In the analogue synthesis front, efforts have been centered on the simplification of the 26-membered macrolactone backbone. Herein, we report the synthesis of a ring expanded analogue **1** (Scheme 1), which retains all the functionalities in the bryostatins, and its biological activities against several cancer cell lines.

Shown in Scheme 1 is our retrosynthetic analysis. Inspired by the B-ring and C-ring segments, we developed a Ru-catalyzed tandem process⁹ for the synthesis of 4-methylene-*cis*-2,6-tetrahydropyran and a Pd(II)-catalyzed tandem reaction¹⁰ for the synthesis of dihydropyrans. Since our Pd(II)-catalysis necessitates an early installation of the sensitive α,β -unsaturated methyl ester at C(13), we decided to evaluate a ring-closing metathesis (RCM) approach for the formation of the macrocycle.^{11,12} The steric hindrance of the C(16)–C(17) double bond (bryostatins numbering) made this approach risky, but we were encouraged by the potential to access ring-expanded analogues.¹³

Our synthesis of the northern hemisphere **2** is outlined in Scheme 2. The alcohol **9**¹⁴ was converted to the hydroxyketone **12** following a procedure⁵ from Evans. Subsequent hydroxyl-directed *anti*-reduction,¹⁵ lactonization,¹⁶ and protection gave lactone **14**. At this stage, a β,γ -unsaturated ketone was introduced to give **5**. The key Ru-catalyzed tandem coupling between enone **5** and homopropargylic alcohol **4** furnished tetrahydropyran **15** in 56% yield as a 9:1 *cis:trans* diastereomeric mixture, no double bond isomer was observed. Although excess **5** (2.2 equivalents) were used in the reaction, 1.2 equivalents were recovered and recycled. Subsequent bromination and deprotection gave the corresponding diol, which was subjected to a tandem lactone methanolysis–ketolization to afford **16**. Compound **16** was converted to vinyl bromide **16** and then the northern hemisphere **2** in 8 steps.

Our synthesis of the southern hemisphere **3** commenced with D-glactonic acid 1,4-lactone (Scheme 3). Epoxide opening of **18**¹⁷ with methyl propionate delivered methyl ynoate **19**,

which was coupled with alkyne **20**¹⁸ under our tandem Pd(II)–catalysis conditions to give dihydropyran **21** in 55% yield.¹⁹ At this stage, the vicinal oxygens at C(19) and C(20) were introduced via an epoxidation. Unfortunately, stereochemistry of the newly introduced C(20)–hydroxyl group was the opposite required for our synthesis. This undesired selectivity was overcome by a Dess-martin oxidation²⁰/Luche reduction²¹ sequence. After introducing a terminal olefin via a Takai olefination²² and a Negishi cross coupling²³, the resulting triene **24** was hydrolyzed and monosilylated to give the southern hemisphere **3**, which was then coupled with **2** in the presence of 2-methyl-6-nitrobenzoic acid anhydride²⁴ to give **25**. Gratifyingly, treatment of **25** with Grubbs-Hoveyda catalyst²⁵ gave 31-membered lactone **26** as an inseparable 1:1 E:Z mixture in 80% yield.²⁶ Final deprotection gave triols **1** and **27**, which were separated by preparative TLC.

The compounds **1** and **27** were tested against several cancer cell lines. Particularly impressive and interesting is the ability of **1** to inhibit the growth of NCI-ADR—a breast cancer cell line with added multi-drug resistant pumps—with an IC₅₀ of 123 nM.²⁷

In summary, a ring expanded bryostatin analogue **1** with potent anti-tumor activity against NCI-ADR cancer cell line was synthesized. Notable features include a Ru–catalyzed tandem tetrahydropyran formation, a Pd–catalyzed tandem dihydropyran formation, and a ring-closing metathesis. The chemistry reported herein should be applicable to future syntheses of the bryostatins and their analogues.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We thank NIH General Medical Science (GM 13598), NSF, and fellowships from Amgen (H.Y), Bristol-Myers Squibb (H.Y), the Alexander-von-Humboldt foundation (O.R.T), NIH (A.J.F), NSF (C.S.B), and ARCS (C.S.B) for their generous financial support; We thank Dr. Hugo Menzella from Kosan Biosciences for testing the biological activities of compounds **1** and **27**, and Dr. Yong Li for helpful discussion; We thank Professor Deryn Fogg, Jay Conrad, Professor Robert Grubbs, and Dr. Tobias Ritter for providing samples of catalysts. Mass spectra were provided by the Mass Spectrometry Regional Center of the UCSF, supported by the NIH Division of Research Resources.

References

1. For a recent review, see: Hale KJ, Hummersone MG, Manaviazar S, Frigerio M. *Nat. Prod. Rep* 2002;19:413. [PubMed: 12195811]
2. (a) El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. *Clin. Cancer Res* 2006;12:7059. [PubMed: 17145828] (b) Pagliaro LC, Perez CA, Tu S-M, Daliani DD. *Urol. Oncol.-Semin. Ori* 2006;24:487. and references therein
3. For recent examples, see: (a) Wender PA, Horan JC, Verma VA. *Org. Lett* 2006;8:5299. [PubMed: 17078702] (b) Wender PA, Horan JC. *Org Lett* 2006;8:4581. [PubMed: 16986955] (c) Keck GE, Welch DS, Vivian PK. *Org Lett* 2006;8:3667. [PubMed: 16898787] (d) Keck GE, Truong AP. *Org. Lett* 2005;7:2153. [PubMed: 15901157] (e) Cho C-W, Krische MJ. *Org. Lett* 2006;8:891. [PubMed: 16494467] (f) Ball M, Bradshaw BJ, Dumeunier R, Gregson TJ, MacCormick S, Omori H, Thomas EJ. *Tetrahedron Lett* 2006;47:2223. (g) Voight EA, Seradj H, Roethle PA, Burke SD. *Org. Lett* 2004;6:4045. [PubMed: 15496095]
4. Kageyama M, Tamura T, Nantz MH, Roberts JC, Somfai P, Whritenour DC, Masamune S. *J. Am. Chem. Soc* 1990;112:7407.
5. (a) Evans DA, Carter PH, Carreira EM, Prunet JA, Charette AB, Lautens M. *Angew. Chem., Int. Ed. Engl* 1998;37:2354. (b) Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J. Am. Chem. Soc* 1999;121:7540.

6. Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S. *Angew. Chem., Int. Ed. Engl* 2000;39:2290. [PubMed: 10941067]
7. Manaviazar S, Frigerio M, Bhatia GS, Hummersone MG, Aliev AE, Hale KJ. *Org Lett* 2006;8:4477. [PubMed: 16986929]
8. Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacote E, Lippa B, Nell PG, Turner TM. *J. Am. Chem. Soc* 2002;124:13648. [PubMed: 12431074]
9. Trost BM, Yang H, Wuitschik G. *Org Lett* 2005;7:4761. [PubMed: 16209529]
10. Trost BM, Frontier AJ. *J. Am. Chem. Soc* 2000;122:11727.
11. The Julia olefination, a well-established method in the previous three total syntheses, for the construction of the macrocycle is unlikely to work for our system due to the basicity of this procedure, see Ref 5b.
12. For a recent review, see: Nicolaou KC, Bulger PG, Sarlah D. *Angew Chem Int Ed Engl* 2005;44:4490. [PubMed: 16003791]
13. Our efforts to construct the bryostatin macrocycle via a RCM reaction met with no success, details will be reported in full account of our work. For another RCM approach by Thomas and co-workers, see ref. ^{3f}.
14. (a) Shiina I, Shibata J, Ibuka R, Imai Y, Mukaiyama T. *Bull. Chem. Soc. Jpn* 2001;74:113. (b) Blakemore PR, Browder CC, Hong J, Lincoln CM, Nagornyy PA, Robarge LA, Wardrop DJ, White JD. *J. Org. Chem* 2005;70:5449. [PubMed: 15989326]
15. Evans DA, Chapman KT, Carreira EM. *J. Am. Chem. Soc* 1988;110:3560.
16. Otera J, Yano T, Kawabata A, Nozaki H. *Tetrahedron Lett* 1986;27:2383.
17. Roy R, Rey AW, Charron M, Molino R. *Chem. Commun* 1989:1308.
18. Synthesized in three steps from 3-methyl-2-butanone. See supporting information for details.
19. This reaction is reproducible at 0.3 mmol scale. For large scale reactions, a two step procedure of Pd(OAc)₂-catalyzed cross coupling of **17** and **18** to form a ene-yne adduct followed by PdCl₂(CH₃CN)₂-catalyzed cycloisomerization was performed. See supporting information for details.
20. Dess DB, Martin JC. *J. Am. Chem. Soc* 1991;113:7277.
21. Luche JL, Rodriguez-Hahn L, Crabbe P. *Chem. Commun* 1978:601.
22. Takai K, Nitta K, Utimoto K. *J. Am. Chem. Soc* 1986;108:7408.
23. Negishi E. *Acc. Chem. Res* 1982;15:340.
24. Shiina I, Kubota M, Oshiumi H, Hashizume M. *J. Org. Chem* 2004;69:1822. [PubMed: 15058924]
25. Garber SB, Kingsbury JS, Gray BL, Hoveyda AH. *J. Am. Chem. Soc* 2000;122:8168.
26. Under this and several other conditions, relay ring-closing metathesis (RRCM) didn't occur, for a leading reference on RRCM, see: Hoye TR, Jeffrey CS, Tennakoon MA, Wang J, Zhao H. *J. Am. Chem. Soc* 2004;126:10210. [PubMed: 15315410]
27. Compound **27** is about 9 fold less active than **1** against NIC-ADR cell line. Epothilone D and discodermolide display IC₅₀ values of 10 and 240 nM respectively in the same assay, see: (a) Hearn BR, Zhang D, Li Y, Myles DC. *Org Lett* 2006;8:3057. [PubMed: 16805551] (b) Shaw SJ, Sundermann KF, Burlingame MA, Myles DC, Freeze BS, Xian M, Brouard I, Smith AB III. *J. Am. Chem. Soc* 2005;127:6532. [PubMed: 15869264]

Scheme 2.a.

^a Reagents and conditions: (a) TBSOTf, Et₃N, -78 °C, 94%; (b) 9-BBN, then H₂O₂, NaOAc, 93%; (c) TEMPO, KBr, NaOCl, CH₂Cl₂/H₂O; (d) Ti(O-*i*-Pr)₂Cl₂, **11**, toluene, -78 °C, 69% over two steps, ~10:1 dr at C(5); (e) Me₄NBH(OAc)₃, AcOH/CH₃CN, -35 °C, 96%, 15:1 dr at C(3); (f) 10 mol% Otera's catalyst **13**, hexane, reflux; (g) TBDPSCl, imid., DMF, 50 °C, quantitative; (h) AcOH/H₂O (4:1), 69%; (i) Dess-Martin Oxidation; (j) allyl iodide, In, DMF, rt, 66% over two steps; (k) Dess-Martin Oxidation, 85%; (l) 10 mol% [CpRu(CH₃CN)₃]PF₆, acetone, rt, 56% yield, dr 9:1; (m) NBS, DMF, 93%; (n) BF₃·OEt₂, 1,3-propanedithiol, CH₂Cl₂, 0 °C, 98%; (o) PPTS, CH₃OH, CH(OCH₃)₃, reflux, 71%; (p) TESCl, DMAP, then pyridine, Ac₂O, 92%; (q) PPTS, MeOH, rt, 85%; (r) DMSO, (COCl)₂, Et₃N, CH₂Cl₂, -78 °C to rt; (s) Ph₃PCH₃Br, *n*-BuLi, 63% over two steps; (t) TBAF, THF, rt, 82%; (u) Me₃SnOH, DCE, 140 °C, microwave, 82%; (v) Pd(PPh₃)₄, CO, DMF/CH₃OH, 85 °C, 94%; (w) TESOTf, 2,6-lutidine, CH₂Cl₂, 68%.

Scheme 3.a.

^a Reagents and conditions: (a) *n*-BuLi, methyl propionate, BF₃·OEt₂, THF, -78 °C, 92%; (b) Pd(OAc)₂, tris(2,6-dimethoxyphenyl)phosphine, **20**, benzene, then Pd(O₂CCF₃)₂, rt, 55%; (c) trifluoroperacetic acid, Na₂HPO₄, CH₂Cl₂/CH₃CN/CH₃OH, 0 °C; (d) Dess-Martin Oxidation; (e) NaBH₄, CeCl₃·7H₂O, -30 °C; (f) Ac₂O, pyridine, DMAP, CH₂Cl₂, rt, 45% over four steps; (g) Et₃N · 3HF, THF, rt, 54–77%; (h) Dess-Martin Oxidation, 94%; (i) CrCl₂, CHI₃, THF, rt, 26% (47% BRSM); (j) Pd(PPh₃)₄, **22**, THF, rt, 68%; (k) AcOH/H₂O (3:1); (l) TESCl, TEA, DMF, -35 °C to -15 °C, 60% over two steps; (m) Et₃N, DMAP, 2-methyl-6-nitrobenzoic acid anhydride, CH₂Cl₂, 51%; (n) benzene, 50–80 °C, 17 mol% Grubbs-Hoveyda Catalyst, 80%, 1:1 *E:Z* mixture; (o) PPTS, MeOH, rt, 36% of **1**, 46% of **27**.